Completed PHASE4 INTERVENTIONAL 1-arm NCT01259557

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm

Sponsor: Medy-Tox

Conditions Essential Blepharospasm

Interventions Botulinum Toxin Type A

Updated 6 times since 2017 Last updated: Apr 24, 2012 Started: Aug 31, 2010 Primary completion: May 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Essential Blepharospasm, this trial is completed. The trial is conducted by Medy-Tox and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medy-Tox

Data source: Medy-Tox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea